NanoViricides Inc. (NNVC)

[changes_iv]

Dengue - Pipeline Review, H2 2013

...report provides information on the therapeutic development for Dengue, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dengue. Scope - A snapshot of the global therapeutic scenario for Dengue. - A review of the Dengue products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Dengue pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned F. Hoffmann-La Roche Ltd. GlaxoSmithKline plc GenVec, Inc. Merck & Co., Inc. Takeda Pharmaceutical Company Limited Biological E. Limited Biotron Limited AVI BioPharma Inc. Medivir AB NanoViricides, Inc. SIGA Technologies, Inc. Panacea Biotec Limited Functional Genetics, Inc. Advinus Therapeutics Pvt. Ltd. Protein Potential, LLC TechnoVax, Inc. MacroGenics, Inc. PTC Therapeutics, Inc. Chimerix, Inc. Wittycell S.A.S. Immunotope, Inc. ImmunoVaccine Technologies Inc. Ortho-McNeil Pharmaceuticals, Inc. and many more...

http://www.barchart.com/headlines/story/132991/dengue-pipeline-review-h2-2013